CHENGDU, China, December 16, 2014 /PRNewswire/ — Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates regarding discussions with industrial leaders in China’s pharmaceutical market to form a potential alliance with the goal to boost revenue for the coming year. In recent years, TPI has made an effort to develop the network organically, yet met challenges due to price competition amid the current healthcare reforms in China. The Company recognizes the revenue decline for the fiscal year 2014 and that to expedite the process of revenue recovery, it is necessary to optimize sales strategies and to ally with well-entrenched industrial leaders to synergize various resources with emphasis on the width and depth of sales networks. The Company hopes the potential alliances could significantly increase core product portfolio sales with positive gross margin trends. The Company will provide prompt updates when these efforts substantiate.
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.
Tel: +86-28-8551-6696 (Chengdu, China)
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tpi-in-talk-with-industrial-leaders-on-alliance-to-boost-revenue-for-2015-300009992.html